Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cyclin T2 (CCNT2) is a regulatory protein encoded by the CCNT2 gene, part of the cyclin family characterized by cell cycle-dependent variation in abundance. It forms a core component of the CDK9/cyclin T complex (also known as positive transcription elongation factor b, P-TEFb), essential for phosphorylation of the RNA polymerase II C-terminal domain and thus for transcriptional elongation of many genes. Cyclin T2 plays roles in muscle differentiation, early viral transcription events (HIV, herpes simplex virus), and interacts with key cell cycle regulators like the Retinoblastoma protein. Multiple isoforms exist due to alternative splicing. Cyclin T2 is considered a target primarily in the context of viral transcription (HIV-1, herpesvirus) and is being explored for therapeutic disruption of these processes. Broader disease association is limited based on current sources.
Inhibition of P-TEFb (CDK9/cyclin T2 complex) disrupts phosphorylation of RNA polymerase II, blocking transcriptional elongation—this mechanism is closely studied in HIV research. Modulation of MYOD1-dependent transcription via interaction with PKN1, affecting muscle gene expression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cyclin T2 (CCNT2).